New Therapies for Hepatitis C Virus Infection
Open Access
- 1 February 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (3) , 313-320
- https://doi.org/10.1086/595848
Abstract
Chronic hepatitis C virus (HCV) infection remains a global health threat with ∼175 million carriers worldwide. Currently, treatment consists of pegylKeywords
This publication has 57 references indexed in Scilit:
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy†Hepatology, 2008
- Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?Journal of Antimicrobial Chemotherapy, 2008
- In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseAntimicrobial Agents and Chemotherapy, 2008
- Viral Hepatitis in HIV InfectionNew England Journal of Medicine, 2007
- Viral Hepatitis and Liver TransplantationSeminars in Liver Disease, 2006
- VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon CellsAntimicrobial Agents and Chemotherapy, 2006
- 78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysisJournal of Hepatology, 2006
- The culture of designing hepato-biliary randomised trialsJournal of Hepatology, 2006
- Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B PolymeraseJournal of Biological Chemistry, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005